Desai, Sanjal
Kim, Chul
Veytsman, Irina
Article History
First Online: 13 August 2019
Compliance with Ethical Standards
:
: Sanjal Desai declares that she has no conflict of interest. Chul Kim received one-time travel support from Caris Life Sciences to an advisory board meeting in 2017; is the site PI for the CANOPY-1 trial (NCT03631199), funded by Novartis; and has received research support from AstraZeneca for an investigator-initiated trial of durvalumab in patients with viral infection and NSCLC. Irina Veytsman declares that she has no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.